Arch Therapeutics Inc (Arch Therapeutics), operates as a medical device company. The company develops self-assembling barrier technologies to improve interventional wound care outcomes. The company offers hemostasis and sealant products to seal and protect leaking and bleeding tissue. It provides interventional wound care products. Arch Therapeutics’ products are used for adhesion prevention, gastrointestinal anastomosis, burns, diabetic ulcers, pressure ulcers, ocular applications, and others. The company also develops products such as AC5 advanced wound system and AC5 topical hemostat1, a self-assembling peptide (SAP) comprising naturally occurring amino acids. It serves its operation across the US. Arch Therapeutics is headquartered in Framingham, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Arch Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Arch Therapeutics Inc Company Overview
- Arch Therapeutics Inc Company Snapshot
- Arch Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Arch Therapeutics Inc - Pipeline Analysis Overview
- Arch Therapeutics Inc - Key Facts
- Arch Therapeutics Inc - Major Products and Services
- Arch Therapeutics Inc Pipeline Products by Development Stage
- Arch Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Arch Therapeutics Inc Pipeline Products Overview
- AC5 - Adhesion Prevention
- AC5 - Adhesion Prevention Product Overview
- AC5 - Burns
- AC5 - Burns Product Overview
- AC5 - Ocular Applications
- AC5 - Ocular Applications Product Overview
- AC5 - V
- AC5 - V Product Overview
- AC5 - V Clinical Trial
- AC5 Surgery - Fluid Barrier
- AC5 Surgery - Fluid Barrier Product Overview
- AC5 Surgery - Laparoscopic Procedures
- AC5 Surgery - Laparoscopic Procedures Product Overview
- AC5 Surgery - Open Procedures
- AC5 Surgery - Open Procedures Product Overview
- AC5 Surgery - Sealant
- AC5 Surgery - Sealant Product Overview
- AC5-G
- AC5-G Product Overview
- Arch Therapeutics Inc - Key Competitors
- Arch Therapeutics Inc - Key Employees
- Arch Therapeutics Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Arch Therapeutics Inc, Recent Developments
- Nov 09, 2023: Arch Therapeutics Provides Year End Operational Update
- Nov 02, 2023: Arch Therapeutics to Present AC5 Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
- Sep 13, 2023: Arch Therapeutics Provides AC5 Commercialization Update
- Apr 05, 2023: Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5 Advanced Wound System now in effect
- Mar 09, 2023: Arch Therapeutics’ AC5 advanced wound system receives dedicated HCPCS billing code from The Centers for Medicare & Medicaid Services
- Mar 07, 2023: Arch Therapeutics announces addition of contract sales force to advance commercialization of AC5 advanced wound system in government facilities
- Oct 18, 2022: Key opinion leaders presented Arch Therapeutics AC5 advanced wound system at 2022 Symposium on Advanced Wound Care (SAWC) Fall
- Oct 11, 2022: Arch Therapeutics’ AC5 advanced wound system to be presented with honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
- Sep 23, 2022: Arch Therapeutics announces first shipments of AC5 advanced wound system under new reimbursement support program
- Sep 20, 2022: Arch Therapeutics accepted to present AC5 Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Arch Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Arch Therapeutics Inc Pipeline Products by Equipment Type
- Arch Therapeutics Inc Pipeline Products by Indication
- Arch Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Arch Therapeutics Inc, Key Facts
- Arch Therapeutics Inc, Major Products and Services
- Arch Therapeutics Inc Number of Pipeline Products by Development Stage
- Arch Therapeutics Inc Pipeline Products Summary by Development Stage
- Arch Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Arch Therapeutics Inc Ongoing Clinical Trials Summary
- AC5 - Adhesion Prevention - Product Status
- AC5 - Adhesion Prevention - Product Description
- AC5 - Burns - Product Status
- AC5 - Burns - Product Description
- AC5 - Ocular Applications - Product Status
- AC5 - Ocular Applications - Product Description
- AC5 - V - Product Status
- AC5 - V - Product Description
- AC5 - V - Study to Differentiate the Key Benefits of Advanced Wound System (A Multi-Site Clinical Study)
- AC5 Surgery - Fluid Barrier - Product Status
- AC5 Surgery - Fluid Barrier - Product Description
- AC5 Surgery - Laparoscopic Procedures - Product Status
- AC5 Surgery - Laparoscopic Procedures - Product Description
- AC5 Surgery - Open Procedures - Product Status
- AC5 Surgery - Open Procedures - Product Description
- AC5 Surgery - Sealant - Product Status
- AC5 Surgery - Sealant - Product Description
- AC5-G - Product Status
- AC5-G - Product Description
- Arch Therapeutics Inc, Key Employees
- Glossary
- Arch Therapeutics Inc Pipeline Products by Equipment Type
- Arch Therapeutics Inc Pipeline Products by Development Stage
- Arch Therapeutics Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Plus Therapeutics Inc
- Inovio Pharmaceuticals Inc
- Arthrex Inc
- Antares Pharma Inc
- Anika Therapeutics Inc
